BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 16, 2009
 |  BioCentury  |  Politics, Policy & Law

Waxman vs. Eschoo

Waxman vs. Eschoo

Waxman et al. Eshoo et al.
Initial data exclusivity Five years for new molecules, three years for a new biologic where a "major substance" in that new biologic had been approved previously. Exclusivity apparently only would be applied to biologics approved after enactment of the law. 12 years for all biologics.
Data exclusivity extension for new indication Six months for approval of a medically significant new application (reduced to three months if gross U.S. sales exceeded $1B for the year prior to approval of the new...

Read the full 525 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >